中性粒细胞淋巴细胞比值和动静脉二氧化碳分压差在呼吸衰竭诊治中的研究进展

Research advances in neutrophil-to-lymphocyte ratio and arteriovenous carbon dioxide gradient in diagnosing and treating respiratory failure

呼吸衰竭是临床上常见的危重疾病,是重症监护病房患者常见的死亡原因之一。随着医学技术的不断进步,呼吸衰竭致残率与死亡率明显下降,但仍有大量患者的致残率比较高,严重威胁人们的生活质量。本文概述了呼吸衰竭的发病现状与治疗措施,分析了中性粒细胞淋巴细胞比值与动静脉二氧化碳分压差(Pcv-aCO_(2))的临床使用价值,重点探讨了中性粒细胞淋巴细胞比值和动静脉二氧化碳分压差在呼吸衰竭疾病诊治中的研究进展,并进行了研究展望。希望本综述能促进临床对呼吸衰竭的早期诊断、病情判断与预后预测。

Respiratory failure is a prevalent critical illness in clinical practice and is one of the common causes of death in intensive care unit patients.With the continuous progress of medical technology,the disability rate and mortality rate of respiratory failure have decreased markedly,but a large number of patients still have high disability rates,posing a serious threat to individuals'quality of life.This article reviews the current status and treatment of respiratory failure,analyzes the clinical value of neutrophil-to-lymphocyte ratio and central venous-to-arterial carbon dioxide difference(Pcv-aCO_(2)),with a focus on discussing the research advances of neutrophil-to-lymphocyte ratio and Pcv-aCO_(2)in diagnosing and treating respiratory failure,followed by a research prospect.It is hoped that this review will promote the early diagnosis,disease judgment,and prognosis prediction of respiratory failure clinically.